DOM-ALENDRONATE-FC 70 MG
ALENDRONIC ACID (ALENDRONATE SODIUM) : 70 MG · DIN 02308398 · DOMINION PHARMACAL
Health Canada status: CANCELLED POST MARKET
What is DOM-ALENDRONATE-FC?
DOM-ALENDRONATE-FC 70 MG contains ALENDRONIC ACID (ALENDRONATE SODIUM) : 70 MG. It is listed in the Health Canada Drug Product Database under DIN 02308398, held by DOMINION PHARMACAL, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 09-May-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DOM-ALENDRONATE-FC used for?
Treatment of osteoporosis in postmenopausal women and in men to reduce the incidence of fractures.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02308398 |
|---|---|
| Brand name | DOM-ALENDRONATE-FC |
| Generic / active ingredient | ALENDRONIC ACID (ALENDRONATE SODIUM) : 70 MG |
| Manufacturer | DOMINION PHARMACAL |
| Strength | 70 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | M05BA04 ALENDRONIC ACID |
| AHFS class | 92:24.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 09-May-2025 |
| Original market date | 2017-02-14 00:00:00 |
How is it administered?
One 70 mg tablet once weekly. Take with full glass of plain water upon arising, at least 30 minutes before first food, beverage, or medication. Do not lie down for 30 minutes.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (refers to STORAGE AND STABILITY section).
How is it supplied?
Not explicitly detailed in provided text (refers to DOSAGE FORMS, COMPOSITION AND PACKAGING section).
Contraindications
Hypersensitivity; esophageal abnormalities (stricture/achalasia); inability to stand/sit upright for 30 mins; hypocalcemia; renal insufficiency (CrCl <35 mL/min).
Warnings and precautions
Can cause local upper GI irritation (esophagitis, ulcers). Osteonecrosis of the jaw and atypical femur fractures reported. Correct hypocalcemia before use. Severe musculoskeletal pain possible.
What can be used instead?
Other Canadian products sharing ATC code M05BA04 ALENDRONIC ACID. 17 of 79 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-ALENDRONATE | 10 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02381486 |
| ACH-ALENDRONATE | 5 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02381478 |
| ACH-ALENDRONATE | 70 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02381494 |
| AG-ALENDRONATE SODIUM | 70 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02506327 |
| ALENDRONATE | 70 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02299712 |
| ALENDRONATE | 70 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02352966 |
| ALENDRONATE-70 | 70 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02303078 |
| APO-ALENDRONATE | 70 MG | TABLET | APOTEX INC | MARKETED | DIN 02248730 |
| AURO-ALENDRONATE | 10 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02388545 |
| AURO-ALENDRONATE | 70 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02388553 |
Who else supplies ALENDRONIC ACID worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ALENDRONIC ACID appears in 140 registered pack listings across 10 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.